Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
US-2017121326-A1 · May 4, 2017 · US
EGFR inhibitor compounds
US11098030B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11098030-B2 |
| Application number | US-201916703544-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 4, 2019 |
| Priority date | May 26, 2016 |
| Publication date | Aug 24, 2021 |
| Grant date | Aug 24, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt of any of the foregoing. 2. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 3. The compound of claim 2 , wherein the compound is 4. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 5. The compound of claim 4 , wherein the compound is 6. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 7. The compound of claim 6 , wherein the compound is 8. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 9. The compound of claim 8 , wherein the compound is 10. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 11. The compound of claim 10 , wherein the compound is 12. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 13. The compound of claim 12 , wherein the compound is
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
- C07D403/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Antineoplastic agents · CPC title
not condensed and containing further heterocyclic rings · CPC title
- A61K31/404Primary
Indoles, e.g. pindolol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11098030B2 cover?
- Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
- Who is the assignee on this patent?
- Recurium Ip Holdings Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D403/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).